


**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANTS**
ATTY. DOCKET NO.
VOS-44 CON

APPLICATION NO.
10/644,325

APPLICANTS
Hans Weiher, et al.

CONFIRMATION NO.
6657

FILING DATE
August 19, 2003

GROUP
1623

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
84	4,758,551	7/19/88	Meister et al.	514	18	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
84	Evans, P., Halliwell, B. "Free Radicals and Hearing: Cause, Consequence, and Criteria," <i>Annals New York Academy of Sciences</i> , 884:19-40 (1999)
01	Hanigan, M. H. et al. "Cisplatin nephrotoxicity: Inhibition of γ -Glutamyl Transpeptidase Blocks the Nephrotoxicity of Cisplatin without Reducing Platinum Concentrations in the Kidney," <i>American Journal of Obstetrics and Gynecology</i> , 175:270-274 (1996)
04	Hanigan, M. H. et al. "Expression of Gamma-Glutamyl Transpeptidase in Stage III and IV Ovarian Surface Epithelial Carcinomas Does Not Alter Response to Primary Cisplatin-Based Chemotherapy," <i>Database Biosis</i> (1998)
01	Hanigan, M. H. et al. "Human Germ Cell Tumours: Expression of Gamma-Glutamyl Transpeptidase and Sensitivity to Cisplatin," <i>British Journal of Cancer</i> , 81:75-79 (1999)
01	Isao, N. et al. "Attenuation of Aminoglycoside Ototoxicity by Glutathione," <i>Database Biosis Online!</i> (1996)
84	Kil, J. et al. "Localization of Gamma-Glutamyl Transpeptidase in the Chick Inner Ear Sensory Epithelia," <i>Society for Neuroscience</i> , 22:1621 (1996)
86	Lopez-Gonzalez, M. A. et al. "Ototoxicity Caused by Cisplatin is Ameliorated by Melatonin and Other Antioxidants," <i>Journal of Pineal Research</i> , 28:73-80 (2000)
84	Townsend, D. M. et al. "In Vivo Metabolism of Cisplatin to a Nephrotoxin by Gamma-Glutamyl Transpeptidase and Beta-Lyase," <i>Proceedings of the American Association for Cancer Research Annual</i> , 41:266 (2000)

EXAMINER

DATE CONSIDERED

6/85

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.